Supplier Will Not Disclose a Formulation: Evidence Options

Confidentiality is not the end of evidence：When a formula is unavailable, the practical task is to build an alternative evidence chain—not to force disclosure

A supplier may withhold a complete formulation because of commercial confidentiality, upstream commitments or competitive sensitivity. That does not make missing information evidence of low risk. For RoHS, REACH, SVHC, POPs, PFAS or customer restricted-substance requests, first define the product, material, use, market, supply-chain role and regulatory question before deciding whether the available records support a traceable conclusion.

For example, REACH article-related duties depend on the substance, concentration, role and other conditions, while a safety data sheet is not a complete composition certificate for every finished article or part. The practical goal is therefore not to treat an SDS, generic declaration or a statement such as 'no hazardous substances' as a final answer. Build evidence in layers around identifiable material, regulatory scope, version, change history and, where needed, analytical results.

Bottom line first

Commercial confidentiality may limit formula disclosure, but it does not end evidence collection or risk assessment.
Start with a dated, signed and material-specific declaration that states the legal and substance scope.
SDSs, technical data sheets and certificates of analysis can add context, but normally do not prove the full restricted-substance status of a finished part.
Controlled third-party review, upstream evidence or non-disclosing composition and use confirmations can narrow an evidence gap.
Where a material-specific high-risk gap remains, targeted testing and change notification are more actionable than waiting for a complete formula.
When evidence is insufficient, document what cannot be confirmed rather than inferring conformity.

Information needed before deciding

Level 1: a dated, signed regulatory or substance-specific declaration for an identified material or part, stating regulation, substance group, threshold and model scope.
Level 2: a material specification, technical data sheet, certificate of analysis, use statement or intentional-use statement that does not disclose the complete formula.
Level 3: upstream evidence, an independent review subject to an NDA, or a controlled third-party confirmation of confidential data scope.
Level 4: targeted analytical evidence designed for the material, substance and use question, with sample, method, analytes and reporting limits retained.
Level 5: continuing BOM and material mapping, supplier qualification, change notifications, risk decisions and escalation records.
The levels can be combined. Their adequacy depends on the applicable law, customer requirement, material risk and quality of the records—not on a single document label.

Practical decision flow

Define the regulatory question

Document the product, material, market, regulation or customer specification, substance scope and intended use of the evidence. Do not make full-formula disclosure the only possible request.

Request Level 1 declaration first

Ask the supplier to link the declaration to material grade, part number, revision, manufacturing site or batch and state the covered regulation and substance scope.

Use Levels 2 and 3 to narrow confidential gaps

Collect material specifications, use data, upstream evidence or controlled third-party confirmations without requesting full percentage formulation; record what remains unverified.

Verify material-specific high-risk gaps

Where material, use or contamination pathways create a reasonable concern, select samples and analytes that answer that gap rather than treating an unrelated broad report as proof.

Apply change and escalation rules

Set notification and reassessment triggers for formula, grade, upstream source, processing aid, recycled content, coating or manufacturing-location changes.

What different evidence can support

Evidence	What it can support	Important limitation
Level 1: material- or part-specific regulatory declaration	A supply-chain claim for an identified material, part, revision and stated legal scope.	A generic declaration without substance scope, threshold, version, signatory or material mapping has limited evidential value.
Level 2: material specification, technical data sheet and certificate of analysis	Material grade, key properties, batch information and partial composition or use information that can be checked against product structure.	These records normally are not a complete restricted-substance inventory or legal-conformity certificate.
Level 3: upstream evidence or controlled third-party confirmation	That upstream records, a specific use, a substance group or a defined review scope has been examined without disclosing the formula to every customer.	State what the reviewer examined, the limits of review and the conclusion. A confidential review does not establish product-wide evidence.
Level 4: targeted test report	Results for the stated sample, method, analytes and reporting limits.	It cannot be automatically extended to untested materials, different formulations, different revisions or unaddressed PFAS or other substance scopes.
Level 5: BOM, material mapping and change record	How declarations, specifications and reports connect to actual products, parts, batches or revisions, and when reassessment is required.	It does not itself supply chemical concentration information and must be read with other evidence.
SDS and process or intentional-use statement	Hazard and supply-chain information for a supplied substance or mixture, or a defined-use statement answering a specific question.	An SDS may not apply to a finished article and normally cannot prove every substance, impurity or undisclosed processing aid in a part.

Common mistakes

Mistake：Stop asking when the supplier says 'confidential'.

**Risk：**The company has no evidence that supports the identified product, material or revision conclusion.

**Better approach：**Ask for disclosable substance scope, material specification, use, version, upstream confirmation and change controls.

Mistake：Treat an SDS as a full formula or a certificate for every product.

**Risk：**Its scope, article applicability, unlisted substances and material mapping can be misunderstood.

**Better approach：**Use the SDS as one input and cross-check it against material declarations, BOM mapping and test scope.

Mistake：Accept a generic declaration with no model, date or regulatory scope.

**Risk：**It may not relate to the actual material, current Candidate List or customer request.

**Better approach：**Request material- or part-specific declarations with version, signature, substance scope and applicability conditions.

Mistake：Read 'not intentionally added PFAS' as 'no PFAS of any kind'.

**Risk：**Intentional addition, impurities, residues, analytical scope and PFAS definitions can be confused.

**Better approach：**Record the exact wording and scope; consider targeted analysis, total-fluorine screening or other evidence where the question requires it. Total-fluorine screening is only a limited indicator; it does not by itself identify every PFAS or establish every requirement.

Mistake：Collect a one-time document without change notice.

**Risk：**The evidence may no longer map after material, upstream-source or process change.

**Better approach：**Include change notification and reassessment in supplier management and product-file processes.

Mistake：Give an absolute customer conclusion while evidence is missing.

**Risk：**An unknown scope is presented as proof, creating customer, audit or market risk.

**Better approach：**Separate what is evidenced from what is not, then decide on records, testing, material substitution or escalation.

Company action checklist

Create a material- and part-specific declaration template covering legal scope, substance scope, version, signing date and product applicability.
Record which Level 1 to Level 5 evidence is present and missing for each confidential material.
Map BOM, material grade, part number, supplier and product revision in a searchable record.
Define acceptable controlled-review or targeted-testing conditions for high-risk uses.
Add notification for formula, raw material, recycled content, process, site and source changes to supplier controls.
Distinguish supplier claims, analytical results and unresolved items in customer responses.
Set reassessment points for regulation, customer specification and market changes.

Manager summary

A confidential formulation is not a reason to stop evidence collection. Management should connect material identity, legal scope, declaration version, upstream or controlled review, targeted analysis and change notification in a traceable chain. If a gap remains, state it clearly and decide whether to obtain more records, verify the material or substitute it rather than presenting confidentiality as proof of conformity.

Frequently asked questions

Can RoHS or REACH be assessed if the supplier will not disclose a formula?

Often some assessment is still possible. Define the material and regulatory question, then combine scoped declarations, material data, upstream or controlled review, testing and change records. If evidence is insufficient, retain a limited or unconfirmed conclusion.

Can an SDS replace a supplier declaration?

Usually not. An SDS is valuable supply-chain information, but it is not normally a complete composition record, a part-level substance inventory or a declaration against a customer-specified requirement.

May a company request a PFAS-free declaration?

It may ask a question aligned to the product, substance definition and use. Do not confuse not intentionally added, non-detection for selected analytes and absence of every PFAS. Record the exact scope and limitation of the response.

Does a third-party review under an NDA help?

Where commercially appropriate, it can reduce a confidential-data gap. Document what the reviewer saw, what criteria were used, the applicable scope and what remains outside the review.

Must a product be retested whenever the formula is unavailable?

There is no universal answer. Compare existing declarations, material data, upstream evidence, historical reports, change history and the specific risk first. Targeted testing may be one way to strengthen a remaining gap.

Does REACH Article 33 require disclosure of a complete formula?

Article 33 duties depend on the applicable conditions, and its minimum information requirement is not full-formula disclosure. Confirm the legal role, product facts and current law before drawing a conclusion.

Official legislation and reference material

Regulation (EC) No 1907/2006 (REACH): Articles 31, 33 and 36

European Union

Legal status: In-force EU Regulation; consult the current EUR-Lex consolidated version and amendments for the authoritative legal text.
Last checked: 2026-08-08
Publication / update date: 2026-05-11 (current consolidation)
Used for: problem, quickConclusion, decisionData, evidence, faqs

Candidate List obligations

European Chemicals Agency (ECHA)

Legal status: Official ECHA explanatory guidance on Candidate List-related obligations; it does not replace the REACH Regulation or a role-specific assessment.
Last checked: 2026-08-08
Publication / update date: Publication/update date not stated on the linked official page; checked 2026-08-08.
Used for: problem, decisionData, workflow, faqs

Safety data sheets